One Organic Chemist One Day............Honouring Profiles of leading Organic Chemists brought to you by DR ANTHONY MELVIN CRASTO, worlddrugtracker, helping millions, amcrasto@gmail.com, +91 9323115463, India, skype amcrasto64
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution
Alexandra Glucksmann,Ph.D., Chief Operating Officer at Editas Medicine Inc.
Alexandra
Glucksmann is Chief Operating Officer and founding employee at Editas
Medicine Inc., a gene editing company whose mission is to translate its
genome editing technology into a novel class of human
therapeutics. Previously, Alexandra was Senior Vice President of
Research and Developmentat Cerulean Pharma, which she
joined at its founding. Cerulean Pharma is a clinical-stage company
developing innovative nanopharmaceutical tumor-targeting products.
Prior to joining Cerulean in 2006, she spent 13 years at Millennium
Pharmaceuticals which she joined in 1993 as one of its first
scientists. At Millennium, she held a series of science positions with
increasing responsibility, ultimately becoming Vice President of all
platform technology groups before moving into a senior role in strategic
program management and operations. She serves on the board of Women in
the Enterprise of Science and Technology (WEST). Alexandra was a
post-doctoral fellow at the Massachusetts Institute of Technology and
holds a Ph.D. with honors from the University of Chicago.
Ms. Alexandra Glucksmann, PhD. has been Chief Operating Officer at
Editas Medicine Inc. since April 2015. Prior to joining Editas Medicine,
she served as Senior Vice President of Research and Business Operations
at Cerulean Pharma Inc. (formerly, Tempo Pharmaceuticals Inc.) There,
she was a founding employee and key contributor to all aspects of
building the company, including setting strategy, analyzing product
development opportunities, cultivating platform and product
partnership prospects, and participating in fundraising activities.
Prior to joining Cerulean in 2006, Alexandra spent 13 years at
Millennium Pharmaceuticals, which she joined in 1993 as one of its first
scientists. At Millennium, she held a series of positions with
increasing responsibility and was critical in helping Millennium evolve
from a genomics research-focused organization to a fully integrated
pharmaceuticals company with marketed products. Her division played an
integral role in Millennium’s numerous large pharma collaborations,
which generated more than $1.8 billion in funding for the company. She
serves on the board of directors of Taconic Farms and is the chair of
the Board of Women Entrepreneurs in Science and Technology (WEST). She
is also a member of the Advisory Council of the Harvard Partners Center
for Personalized Genetic Medicine. Ms. Glucksmann was a post-doctoral
fellow at the Massachusetts Institute of Technology. Ms. Glucksmann
holds as Ph.D. with honors from the University of Chicago.
Alexandra joined Editas Medicine in November 2013 and is the Chief Operating Officer.Prior
to joining Editas Medicine, Alexandra was senior vice president of
research and business operations from 2006 until June 2013 at Cerulean
Pharma, a clinical-stage company developing innovative
nanopharmaceutical tumor-targeting products. There, she was a founding
employee and key contributor to all aspects of building the company,
including setting strategy, analyzing product development opportunities,
cultivating platform and product partnership prospects, and
participating in fundraising activities. Prior to joining Cerulean in
2006, Alexandra spent 13 years at Millennium Pharmaceuticals, which she
joined in 1993 as one of its first scientists. At Millennium, she held a
series of positions with increasing responsibility and was critical in
helping Millennium evolve from a genomics research-focused organization
to a fully integrated pharmaceuticals company with marketed products.
Her division played an integral role in Millennium’s numerous large
pharma collaborations, which generated more than $1.8 billion in funding
for the company. She serves as the chairperson of the Board of
Directors of Women Entrepreneurs in Science and Technology (WEST).
Alexandra was a post-doctoral fellow at the
Massachusetts Institute of Technology and holds a Ph.D. with honors from
the University of Chicago and a B.S. in molecular biology from the
University of Wisconsin.
Dr. Jo Viney, Vice President, Immunology Research at Biogen
Dr.
Jo Viney is Vice President, Immunology Research at Biogen in Cambridge,
MA. In this role, Jo is responsible for setting scientific research
direction and strategy with a focus on target identification and
validation for drug discovery and development for treating patients with
autoimmune and inflammatory diseases. Jo received her PhD from St
Bartholomew’s Hospital, University of London in 1991 and pursued
postdoctoral fellowships first at the Imperial cancer Research Fund in
London, UK, and at Genentech in the Bay Area, California. Following her
training, Jo joined Immunex in 1995 and remained at the company, which
was acquired by Amgen in 2002, until leaving to join Biogen Idec. Jo has
advanced a portfolio of novel biologic and small molecule programs,
seven of which have progressed to IND and into clinical development, for
diseases such rheumatoid arthritis, asthma, atopic dermatitis,
psoriasis, inflammatory bowel disease and lupus. Jo has maintained
longstanding membership with the American Society of Immunologists
(AAI), the British Society for Immunology (BSI) and the Society for
Mucosal Immunology (SMI). She served as President of SMI from 2011-2013.
Together with her SMI colleagues, she launched the journal Mucosal
Immunology with Nature Publishing Group in 2007. Jo has been a member of
the Scientific Advisory Board for Keystone Symposia since 2008, and she
partners with KS on a number of programs for under-represented
scientists. She is also member of the Scientific Advisory Board for the
BioAster Technology Research Institute (IRT) in France, and for Vaxart
Inc in the Bay Area.
My particular area of interest revolves around understanding the
mechanistic basis of immune homeostasis in organs susceptible to
inflammatory disease. Past work has included investigating tolerogenic
antigen presentation in the intestine, developing new mouse models of
colitis and studying the function of novel butyrophilin-like (BTNL)
inhibitory molecules.
I am the vice president of the immunology research group at Biogen.
The group’s mission is to develop treatments for underserved
immune-mediated inflammatory diseases associated with autoimmunity and
fibrosis. Research extends from basic target identification and
validation through to drug discovery and preclinical development.
Education
Postdoc, Genentech, UK and USA, 1995
Postdoc, Imperial Cancer Research Fund, UK, 1994
Ph.D., St Bart’s Hospital, University of London, London, UK, 1991
B.Sc., University of East London, London, UK, 1987
The tale of TL1A in inflammation. Mucosal Immunol. 2011 Jul;4(4):368-70. doi: 10.1038/mi.2011.20. Epub 2011 May 4. Review. Hsu H, Viney JL.
PMID: 21544073
Dr. Rachel Meyers, Senior Vice President, Research at Alnylam Pharmaceuticals
Dr.
Rachel Meyers is Vice President of Research and RNAi Lead Development
(RLD) at Alnylam. In this capacity, she plays a key role in the
advancement of Alnylam’s RNAi therapeutic programs, from early discovery
through clinical development and her team is responsible for program
leadership for most of Alnylam’s preclinical and clinical stage
programs. In addition to leading the research organization, Dr. Meyers
has worked closely with Alnylam’s business development group, playing an
integral part in establishing important collaborations, and has
functioned as a scientific lead in collaborations with Novartis, Takeda,
Isis, Roche and Genzyme. She also led the scientific diligence
resulting in Alnylam’s acquisition of the Sirna assets from Merck. Prior
to taking on the leadership of the Research and RLD Groups, Dr. Meyers
was one of Alnylam’s Research Directors, focusing her efforts on the
development of RNAi therapeutics to target infectious diseases, and was
the project lead for the company’s RSV program, where she was
responsible for advancing ALN-RSV01 from inception, through pre-clinical
development and into the clinic. Dr. Meyers was honored by Mass High
Tech as one of 10 Women to Watch 2007 and by R & D Directions as one
of its Top 20 Scientists 2007. Before joining Alnylam in April of 2003,
Dr. Meyers was a Senior Scientist at Millennium Pharmaceuticals
(1999-2003) where she was involved in the bioinformatics, molecular and
cell biology of target discovery. Dr. Meyers completed her postdoctoral
training at Harvard Medical School in the field of signal transduction,
and received her Ph.D. from MIT in the field of in vitro transcription. She serves as a Scientific Advisor to Editas Medicine.
.
Studied at King Abdulaziz UniversityPast: الثغر النموذجية
Lives in Jeddah, Saudi ArabiaFrom Jeddah, Saudi Arabia
.
